Halozyme Therapeutics (HALO) Total Current Liabilities (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Total Current Liabilities of $363.2 million for Q1 2026, up 141.53% year-over-year from $150.4 million in Q1 2025, and up 105.1% quarter-over-quarter from $177.1 million in Q4 2025.
Halozyme Therapeutics (HALO) Total Current Liabilities (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Total Current Liabilities for 17 consecutive years, with $363.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 141.53% year-over-year to $363.2 million; the TTM figure through Mar 2026 stood at $363.2 million (up 141.53% YoY), while the FY2025 annual figure was $177.1 million, up 27.31% from the prior year.
- Total Current Liabilities advanced to $363.2 million in Q1 2026 per HALO's latest filing, from $177.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $837.2 million in Q3 2025 and bottomed at $91.9 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $186.0 million across 5 years, with a median of $131.6 million in 2024.
- Annual changes were most pronounced in 2023 — Total Current Liabilities sank 41.66% — and 2025, when it soared 669.4%.
- Halozyme Therapeutics' Total Current Liabilities stood at $130.8 million in 2022, then fell by 13.99% to $112.5 million in 2023, then increased by 23.65% to $139.1 million in 2024, then gained by 27.31% to $177.1 million in 2025, then soared by 105.1% to $363.2 million in 2026.
- Business Quant data shows HALO's Total Current Liabilities at $363.2 million in Q1 2026, $177.1 million in Q4 2025, and $837.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 344.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 344.44 Mn |
| Mar 31, 2026 | 363.21 Mn |
| Dec 31, 2025 | 177.09 Mn |
| Sep 30, 2025 | 837.23 Mn |
| Jun 30, 2025 | 134.28 Mn |
| Mar 31, 2025 | 150.38 Mn |
| Dec 31, 2024 | 139.10 Mn |
| Sep 30, 2024 | 108.82 Mn |
| Jun 30, 2024 | 133.36 Mn |
| Mar 31, 2024 | 131.64 Mn |
| Dec 31, 2023 | 112.49 Mn |
| Sep 30, 2023 | 115.19 Mn |
| Jun 30, 2023 | 116.39 Mn |
| Mar 31, 2023 | 91.92 Mn |
| Dec 31, 2022 | 130.79 Mn |
| Sep 30, 2022 | 109.38 Mn |
| Jun 30, 2022 | 199.51 Mn |
| Mar 31, 2022 | 111.69 Mn |
| Dec 31, 2021 | 117.15 Mn |
| Sep 30, 2021 | 113.15 Mn |